12.80
+0.37(+2.98%)
Currency In USD
| Previous Close | 12.43 |
| Open | 12.23 |
| Day High | 13.21 |
| Day Low | 12.23 |
| 52-Week High | 23.09 |
| 52-Week Low | 8.18 |
| Volume | 1.27M |
| Average Volume | 1.35M |
| Market Cap | 984.05M |
| PE | -4.31 |
| EPS | -2.97 |
| Moving Average 50 Days | 10.33 |
| Moving Average 200 Days | 11.67 |
| Change | 0.37 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $673.33 as of November 16, 2025 at a share price of $12.8. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $932.27 as of November 16, 2025 at a share price of $12.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertiseSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutica
Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
Data are being presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual MeetingSAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted p
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology a